The FDA is reviewing the Biologics License Application (BLA) submission from Capricor Therapeutics regarding its therapeutics for Duchenne Muscular Dystrophy (DMD).
4 reports, 2 independent
Updated 02:15
Still developing
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is reviewing the Biologics License Application (BLA) submission from Capricor Therapeutics regarding its therapeutics for Duchenne Muscular Dystrophy (DMD).
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA issued a Complete Response Letter rejecting Capricor's Deramiocel BLA1 source
- FDA initiated review of Capricor's BLA submission for DMD therapeutics.
Keep exploring
Part of
Capricor Therapeutics is seeking regulatory approval from the FDA for therapeutics targeting Duchenne Muscular Dystrophy.Also in this story
- The FDA announced its decision regarding the Advisory Committee for Capricor Therapeutics' drug, deramiocel, on June 26, 2025.
- Capricor Therapeutics is developing therapeutics for Duchenne muscular dystrophy and had a Type A meeting scheduled with the FDA.
The entities involved
Related events
Coverage
Newest first; wire copies grouped- manilatimes.net
- prnewswire.com
- prnewswire.com
- Unknown outlet